Matching articles for "uveal melanoma"

Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • June 24, 2024;  (Issue 1705)
The FDA has approved tebentafusp-tebn (Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic...
The FDA has approved tebentafusp-tebn (Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e107-8 | Show Full IntroductionHide Full Introduction

In Brief: Melphalan (Hepzato) for Uveal Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • September 4, 2023;  (Issue 1684)
The alkylating agent melphalan (Hepzato – Delcath) has been approved by the FDA for treatment of uveal melanoma in adults with unresectable hepatic metastases that affects...
The alkylating agent melphalan (Hepzato – Delcath) has been approved by the FDA for treatment of uveal melanoma in adults with unresectable hepatic metastases that affects <50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Melphalan is available in a kit (Hepzato Kit) that contains a hepatic delivery system for infusion into the hepatic artery. The drug has been available for years in a tablet formulation for treatment of multiple myeloma and palliative treatment of nonresectable epithelial ovarian cancer and in an IV solution for treatment of multiple myeloma.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e148 | Show Full IntroductionHide Full Introduction